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In adults, hepatic complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are
associated with signiﬁcant morbidity and transplantation-related mortality (TRM). However, there is
a paucity of parallel data on the incidence of, and risk factors for, liver injury (LI) and the impact of LI on TRM
in pediatric allo-HSCT recipients. We compared total bilirubin, direct bilirubin, and alanine aminotransferase
values before allo-HSCT and at 1 month, day þ100, and 12 months after allo-HSCT in 248 patients who
received either a myeloablative conditioning (MAC) regimen (n ¼ 109) or a reduced-toxicity/reduced-
intensity conditioning (RTC/RIC) regimen (n ¼ 139). LI was deﬁned as grade 2 hyperbilirubinemia accord-
ing to the National Cancer Institute’s Common Terminology Criteria for Adverse Events 3.0/4.0 (total
bilirubin, >1.95 mg/dL, 1.5 times above the upper limit of normal for our laboratory). Univariate and multi-
variate logistic regression models were used to identify risk factors for LI and TRM. The incidence of LI at 1
month after allo-HSCT was 14.1%. The median bilirubin level was 3.5 mg/dL (range, 1.97 to 32.2 mg/dL). Only
LI as deﬁned by total bilirubin level, but not by direct bilirubin or alanine aminotransferase level, was found to
be a signiﬁcant predictor for TRM. The 1-year TRM was 60.7% (95% conﬁdence interval, 42.6% to 78.7%) in
patients with LI at 1 month after allo-HSCT, compared with 14.6% (95% conﬁdence interval, 9.9% to 19.4%)
(P < .0001) in patients those who did not have liver injury. Multivariate analysis identiﬁed age (P ¼ .03), total
body irradiation (P ¼ .007), bacterial bloodstream infection (BBSI) (P ¼ .001), and invasive fungal infection
(IFI) (P ¼ .002) as signiﬁcant risk factors for developing LI at 1 month. On multivariate analysis for risk factors
for TRM, only LI at 1 month after allo-HSCT (P < .0001), primary graft failure (P ¼ .001), BBSI (P ¼ .003), and
systemic viral infection (P ¼ .04) were identiﬁed as signiﬁcant risk factors for TRM. LI before allo-HSCT
conditioning was not associated with higher TRM. Although the incidence of LI in pediatric allo-HSCT
recipients is low, LI is associated with very high TRM. BBSI and IFI are the primary risk factors for LI.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hepatic complications affect nearly 80% of adult recipi-
ents of allogeneic hematopoietic stem cell transplantation
(allo-HSCT) and are associatedwith signiﬁcantmorbidity and
mortalitydresponsible for up to 15% of transplantation-
related mortality (TRM) [1-5]. Previous studies have
attempted to determine how best to deﬁne liver injury (LI),
incorporating clinical, radiologic, and laboratory ﬁndings [6].
The extent of LI has been deemed more important than its
cause, an important ﬁnding given the difﬁculty of discerning
causes of LI in these complex patients [7,8]. Whereas aspar-
tate aminotransferase (AST), alanine aminotransferase (ALT),
and bilirubin are most commonly used in current clinical
practice [6], which of the myriad liver function test abnor-
malities is truly predictive of TRM remains unclear.
Importantly, the causes of LI before and after allo-HSCT
differ between children and adults. In children, the risk ofedgments on page 917.
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greater risk of LI secondary to hepatitis B and C infections,
alcoholic injury, and other comorbidities. Over the past
decade, signiﬁcant decreases in the incidence of LI and
hepatic graft-versus-host disease (GVHD) and subsequent
improvements in long-term survival have been linked to
less-toxic conditioning regimens and the use of ursodeox-
ycholic acid for liver protection [9].
Previous studies have demonstrated an association of LI
with poor outcome after allo-HSCT [5,8]; however, those
reports focused mainly on adult patients and on LI devel-
oping after allo-HSCT. There is a paucity of data on the inci-
dence of LI in children after allo-HSCT, as well as data
comparing the incidence and impact of LI at various time
points and with different conditioning regimens. Conse-
quently, we sought to study the incidence of LI before and
after allo-HSCT, to identify risk factors for LI, and to compare
the association between LI and TRM in pediatric allo-HSCT
recipients who received myeloablative conditioning (MAC)
versus those who received reduced-intensity (RIC)/reduced-
toxicity conditioning (RTC). Our hypothesis was that MAC
would be associated with a higher rate of LI and, subse-
quently, a higher incidence of TRM.Transplantation.
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The patients included in this retrospective analysis were consecutive
children, adolescents, and young adults who underwent RIC/RTC or MAC
allo-HSCT at New York-Presbyterian Morgan Stanley Children’s Hospital
between April 2000 and September 2011. Indications for allo-HSCT included
a variety of malignant and nonmalignant conditions. Allogeneic sources of
stem cells included bone marrow, peripheral blood stem cells, and umbilical
cord blood. This retrospective study was approved by Columbia University
Medical Center’s Institutional Review Board.
Conditioning Regimens
The MAC regimens (n ¼ 105) included total body irradiation (TBI) þ
cyclophosphamide (120 mg/kg)  thiotepa (10 mg/kg), TBI þ melphalan
(90-135 mg/m2) and 2 alkylators, i.v. busulfan (12.8-16 mg/kg) þ cyclo-
phosphamide (120-200 mg/kg), or i.v. busulfan (12.8-16 mg/kg) þ
melphalan (135 mg/m2). Twelve patients received a MAC regimen that
included gemtuzumab ozogamicin, in addition to i.v. busulfan and
cyclophosphamide, as described previously [10]. The RTC regimens (n ¼ 63)
included ﬂudarabine (150-180 mg/m2) þ i.v. busulfan (12.8-16 mg/kg) 
alemtuzumab, and ﬂudarabine þ cyclophosphamide (200 mg/kg)  rabbit
antithymocyte globulin (8 mg/kg). The RIC regimens (n ¼ 66) included
ﬂudarabine þ i.v. busulfan (6.4-8 mg/kg) and ﬂudarabine (150 mg/m2) þ
cyclophosphamide (60 mg/kg).
GVHD Prophylaxis and Grading
Details on GVHD prophylaxis and grading have been provided previ-
ously [11].
Infection Prophylaxis and Supportive Care
All patients were hospitalized in protective isolation, deﬁned as a single
hospital room with a high-efﬁciency particulate air ﬁltration system and
reverse isolation. All patients received sargramostim (250 mg/m2/day) or
ﬁlgrastim (10 mg/kg/day) either i.v. or s.c. until an absolute neutrophil
count >2500/mm3 was achieved for 3 days, as described previously [12].
Herpes simplex virus prophylaxis consisted of acyclovir (250 mg/m2) i.v.
every 8 hours from day -5 until engraftment and grade II mucositis. Pneu-
mocystis carinii prophylaxis consisted of trimethoprim/sulfamethoxazole up
to day -2, and then resumed 3 times weekly after myeloid engraftment.
Patients unable to tolerate trimethoprim/sulfamethoxazole received i.v.
pentamidine prophylaxis every 2 weeks. Fungal prophylaxis consisted of
liposomal amphotericin B (3 mg/kg/day i.v.) starting on day 0 and
continuing through day þ100, as described previously [13]. Cytomegalo-
virus (CMV) prophylaxis was administered as described previously [14].
After achieving an absolute neutrophil count of >750/mm3 after allo-HSCT,
patients at increased risk of acquiring CMV infection (CMV-positive donor
and/or recipient) received prophylaxis with foscarnet (90mg/kg/dose) every
other day alternating with ganciclovir (5 mg/kg/dose) every other day until
day þ100.
LI Prophylaxis
From 2007 onward, patients were uniformly given ursodiol
30 mg/kg/day for liver protection, starting at 1-7 days before conditioning
and continuing up to day þ30 after allo-HSCT as tolerated. Patients
considered at high risk for veno-occlusive disease (VOD) by the treating
physician received prophylaxis with enoxaparin 1 mg/kg s.c. (maximum,
40 mg) from the start of conditioning through day þ21 after allo-HSCT [15].
Liver Function Monitoring
In all patients, serum total bilirubin, direct bilirubin, and ALT were
measured prospectively 3-4 times per week in the inpatient unit, typically
between the start of conditioning and at least 30 days after allo-HSCT. Most
of the patients who were discharged had values measured twice a week
from day þ30 to day þ100.
Maximum total bilirubin, direct bilirubin, and ALT values were
measured across 2 preeallo-HSCT time blocks: historic (>2 weeks before the
start of conditioning or >1 month before hematopoietic stem cell infusion)
and preconditioning (within 2 weeks before the start of conditioning, or
approximately day -30 to day -15). Posteallo-HSCT values were collected on
an average of 3 days at 1 month (average, day þ28 to day þ30), 100 days
(average, day þ98 to day þ100), and 1 year after allo-HSCT. For outpatient
recipients, data was collected as a single value at each time point. The
preeallo-HSCT blocks were chosen to distinguish between historic and
preconditioning LI and its effects on TRM.
Deﬁnitions
TRM was deﬁned as death due to any cause other than disease
progression or relapse. TRMwas measured from the date of allo-HSCT to thedate of death or December 31, 2011. Patients were censored at the time of
conditioning for a second allo-HSCT or, if they remained alive, on December
31, 2011.
Poor-risk patients were deﬁned as those with chemoresistant malignant
disease, third or greater complete remission, induction failure, progressive
disease, and/or receipt of a second allograft. All other patients with malig-
nant or nonmalignant diseases were deﬁned as average risk.
LI was deﬁned as total bilirubin >1.95 mg/dL, which is grade 2 hyper-
bilirubinemia as deﬁned by the National Cancer Institute’s Common
Terminology Criteria for Adverse Events 3.0/4.0 (speciﬁcally, >1.5 times the
upper limit of normal for our laboratory; the normal total bilirubin value in
our laboratory is 0.3 mg/dL to 1.3 mg/dL).
Of note, although data on direct bilirubin and ALT were collected
initially, these variables were not signiﬁcant predictors of TRM in our
multivariate analysis, and so we limited our analysis to total bilirubin.
Acute kidney injury was deﬁned as a >50% drop in estimated creatinine
clearance compared with baseline as evaluated using the formula of
Schwartz [11].
Invasive fungal infections (IFIs) were divided into candidemia, invasive
aspergillosis, and other fungi and deﬁned using previously published
criteria [16]. Systemic viral infection (SVI) was deﬁned as a positive blood
PCR ﬁnding or as we have previously published [16]. Bacterial bloodstream
infection (BBSI) was deﬁned as a positive blood culture for gram-positive
cocci, gram-negative rods, and atypical mycobacterium.Statistical Methods
Values for continuous variables are presented as mean  standard
deviation, and values for categorical variables are presented as number and
percentage. Between-group comparisons were made using the t-test for
continuous variables and the chi-square test for categorical variables.
Univariate and multivariate logistic regression models were used to identify
risk factors for LI, and the competing-risk regression analysis of Fine and
Gray [17] was used for TRM, with relapse as the competing event. Multi-
variate analysis was performed using factors that had a P value <.20 on
univariate regression analysis, using a stepwise variable selection procedure
with .1 as the entry level and .05 as the stay level. A P value <.05 was
considered to indicate statistical signiﬁcance. All statistical analyses were
performed using SAS 9.2 (SAS Institute, Cary, NC).
Risk factors for LI analyzed included age, sex, year of allo-HSCT, CMV risk
status, disease type (malignant versus nonmalignant), disease risk status,
SVI, BBSI, IFI, acute kidney injury, stem cell source (matched sibling donor/
matched unrelated donor versus umbilical cord blood), conditioning (MAC
versus RTC/RIC), primary graft failure, TBI, enoxaparin prophylaxis, ursodiol
prophylaxis, CD34 selection, and aGVHD prophylaxis with methotrexate.
Risk factors for TRM analyzed included age, sex, year of allo-HSCT, CMV risk
status, disease type and disease risk status, acute and chronic GVHD, VOD,
conditioning regimen, primary graft failure, stem cell source, IFI, BBSI, SVI,
historic and preconditioning LI, and LI at 1 month after allo-HSCT. The
analyses were performed using SAS 9.2 and R with the cmprsk package [18].RESULTS
Patients and Demographics
A total of 248 eligible patients (164 males and 84 females;
mean age, 9.54  6.41 years) underwent allo-HSCT during
the study period. The MAC group comprised 109 patients
(mean age, 8.98  6.07 years), of whom 87 (79.8%) under-
went allo-HSCT formalignant disorders and 22 (20.2%) did so
for nonmalignant disorders. The RTC/RIC group comprised
139 patients (mean age, 9.99  6.66 years), of whom
66 (47.5%) underwent allo-HSCT for malignant disorders and
73 (52.5%) did so for nonmalignant disorders. Data were
initially collected and analyzed independently for the RTC
and RIC groups; however, because the incidence of LI and risk
factors for LI and TRM were nearly identical in these
2 groups, with no statistically signiﬁcant differences, these
2 groups were combined and reanalyzed.
Preeallo-HSCT demographic data for all patients are
displayed in Table 1. There was no statistically signﬁcant
differences between MAC allo-HSCT recipients and RTC/RIC
allo-HSCT recipients in terms of age, sex, body mass index,
CMV risk status, or donor source. However, more children in
the MAC allo-HSCT group underwent transplantation for
Table 1
Pretransplantation Demographic Data for Pediatric Allo-HSCT Recipients
Conditioned with RTC/RIC and with MAC
Characteristic All
(n ¼ 248)
MAC
(n ¼ 109)
RTC/RIC
(n ¼ 139)
P
Value
Age, yr, mean  SD 9.5  6.4 9.0  6.1 10.0  6.7 .22
Sex, n (%)
Male 164 (66) 67 (61) 97 (70) .17
Female 84 (34) 42 (38) 42 (30)
Disease type, n (%)
Malignant 153 (62) 87 (80) 66 (47) <.001
Nonmalignant 95 (38) 22 (20) 73 (52)
Disease status, n (%)
Average-risk group 187 (75) 69 (63) 118 (85) <.001
Poor-risk group 61 (25) 40 (37) 21 (15)
CMV risk status, n (%)
Donor and/or
recipient seropositive
178 (72) 84 (77) 94 (68) .10
Donor and
recipient seronegative
70 (28) 25 (23) 45 (32)
Donor, n (%)
Matched sibling donor 89 (36) 35 (32) 54 (39) .46
Matched unrelated donor 51 (21) 27 (25) 24 (17)
Related cord blood 6 (2) 3 (3) 3 (2)
Unrelated cord blood 102 (41) 44 (40) 58 (42)
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disease (P < .0001).
Posteallo-HSCT characteristics, not including LI, are pre-
sented in Table 2. There were no statistically signiﬁcant
differences in the incidence rates of SVI, IFI, chronic GVHD,
primary graft failure, or VOD between the MAC allo-HSCT
and RTC/RIC allo-HSCT groups. The incidence rates of BBSI
(P ¼ .036) and acute GVHD (P < .0001) were higher in the
MAC allo-HSCT group.Table 2
Post-transplantation Outcomes of Pediatric Allo-HSCT Recipients Condi-
tioned with RTC/RIC and with MAC
Characteristic All (n ¼ 248) MAC RTC/RIC P Value*
SVI (0-30 d) (n ¼ 246)
No 215 (87) 95 (87) 120 (88) .92
Yes 31 (13) 14 (13) 17 (12)
BBSI (0-30 d) (n ¼ 247)
No 188 (76) 76 (70) 112 (81) .04
Yes 59 (24) 33 (30) 26 (19)
IFI (0-30 d) (n ¼ 247)
No 240 (97) 105 (96) 135 (98) .48
Yes 7 (3) 4 (4) 3 (2)
Primary graft failure (n ¼ 243)
No 214 (88) 97 (91) 117 (85) .14
Yes 29 (12) 9 (9) 20 (15)
Acute GVHD (n ¼ 248)
No 148 (60) 50 (46) 98 (70) <.0001
Yes 100 (40) 59 (54) 41 (30)
Chronic GVHD (n ¼ 248)
No 203 (82) 89 (82) 114 (82) .94
Yes 45 (18) 20 (18) 25 (18)
VOD (n ¼ 248)
No 230 (93) 98 (90) 132 (95) .13
Yes 18 (7) 11 (10) 7 (5)
Enoxaparin (n ¼ 247)
No 145 (59) 49 (45) 96 (69) .0002
Yes 102 (41) 59 (55) 43 (31)
Ursodiol (n ¼ 247)
No 155 (63) 62 (57) 93 (67) .13
Yes 92 (37) 46 (43) 46 (33)
Methotrexate (n ¼ 248)
No 212 (86) 88 (81) 124 (89) .06
Yes 36 (14) 21 (19) 15 (11)
All data are n (%).
* Chi-square test.LI
PreeAllo-HSCT
Historic and preconditioning values for total bilirubin for
patients with these data available are presented in Table 3.
Thirty-three patients with a hemoglobinopathy, speciﬁcally
sickle cell disease or thalassemia, were excluded from this
preeallo-HSCT bilirubin analysis, and another 5 patients who
were referred from other institutions for allo-HSCT did not
have historical bilirubin values available. There was no
statistically signiﬁcant difference in historic or pre-
conditioning LI between the MAC allo-HSCT and RTC/RIC
allo-HSCT groups.
PosteAllo-HSCT
The incidence of LI at 1 month, 100 days, and 1 year after
allo-HSCTare listed in Table 3. By 1 month after allo-HSCT, 33
patients (14.1%) had developed LI. The incidence of LI at
1 month was 21.9% in the MAC allo-HSCT group versus 7.8%
in the RTC/RIC allo-HSCT group (P ¼ .0067). In the patients
with LI at 1 month after allo-HSCT, the median total bilirubin
level was 3.5 mg/dL (range, 1.97 to 32.2 mg/dL). There was no
statistically signiﬁcant differences in LI at dayþ100 or 1 year
after allo-HSCT between the MAC and RTC/RIC groups.Risk Factors for Developing LI at 1 Month
Because the incidence of LI after allo-HSCT was highest at
1 month and was substantially decreased by day þ100, we
analyzed risk factors for LI at 1month. On univariate analysis,
the risk factors for developing LI at 1 month after allo-HSCT
with a P value <.20 were age (P ¼ .10), year of allo-HSCT (P ¼
.12), disease risk (P ¼ .0016), BBSI (P < .0001), IFI (P ¼ .0013),
acute kidney injury (P ¼ .0056), stem cell source (P ¼ .09),
MAC (P¼ .0029), TBI (P¼ .002), and aGVHD prophylaxis with
methotrexate (P ¼ .11). Sex, CMV risk status, malignant
disease, SVI, enoxaparin prophylaxis, ursodiol prophylaxis,
and primary graft failure were not signiﬁcant.Table 3
Incidence of Pretransplantation and Post-transplantation LI, Deﬁned by
Total Bilirubin Concentration, in Pediatric Allo-HSCT Recipients Conditioned
with RTC/RIC and with MAC
Total Bilirubin, mg/dL* All
(n ¼ 248)
MAC RTC/RIC P Valuey
Past (>1 mo before allo-SCT) (n ¼ 177)
1.3 102 (58) 52 (62) 50 (54) .51
1.3-1.95 24 (14) 11 (13) 13 (14)
>1.95 51 (29) 21 (25) 30 (32)
Preconditioning
(d -30 to d -15)
(n ¼ 206)
1.3 186 (90) 88 (93) 98 (89)
1.3-1.95 13 (6) 6 (6) 7 (6)
>1.95 7 (4) 1 (1) 6 (5) .23
1 mo after allo-SCT (n ¼ 234)
1.3 189 (81) 76 (72) 113 (87) .007
1.3-1.95 12 (5) 6 (6) 6 (5)
>1.95 33 (14) 23 (22) 10 (8)
Day þ100 after allo-SCT (n ¼ 205)
1.3 190 (93) 75 (89) 115 (95) .10
1.3-1.95 9 (4) 4 (5) 5 (4)
>1.95 6 (3) 5 (6) 1 (1)
1 yr after allo-SCT (n ¼ 128)
1.3 124 (97) 43 (96) 81 (98) .39
1.3-1.95 1 (1) 0 (0) 1 (1)
>1.95 3 (2) 2 (4) 1 (1)
Data are n (%).
* Missing patients were referred from other institutions or underwent
allo-HSCT promptly after diagnosis.
y Chi-square test.
Table 4
Multivariate Analysis for Risk Factors Associated with LI at 1 Month in
Pediatric Allo-HSCT Recipients
Variable OR 95% CI P Value
Age 1.1 1.0-1.2 .03
BBSI
No 1
Yes 5.0 1.9-13.1 .001
IFI
No 1
Yes 44.4 4.0-497.4 .002
TBI
No 1
Yes 4.0 1.5-11.1 .007
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.001), IFI (P ¼ .002), and TBI (P ¼ .007) were signiﬁcant risk
factors for developing LI at 1 month (Table 4).BBSI and IFI
Because BBSI and IFI during the ﬁrst 30 days after allo-
HSCT were highly associated with LI at 1 month, we
analyzed causative organisms in more depth. During the ﬁrst
30 days after allo-HSCT, 18 of the 33 patients experienced
a total of 28 episodes of BBSI (12 gram-negative rods, 10
Staphylococcus spp, 3 Streptococcus spp, and 3 vancomycin-
resistant enterococci). Eight IFIs were noted in 6 patients (5
Candida spp, 1 Aspergillus niger, 1 Malassezia furfur, and
1 Cryptococcus neoformans).TRM
LI and various other transplantation-related factors can
lead to mortality in patients after allo-HSCT. The incidence of
TRM during the study period of 1095  1173.3 days (range,
15-4258 days) was higher in the MAC group compared with
the RTC/RIC group (33.9% [37 of 109] versus 18.1% [25 of 138];
P ¼ .004). We performed univariate proportional competing-
risk regression analysis for risk factors associated with TRM
after RTC/RIC allo-HSCT and MAC allo-HSCT. In terms of LI,
historic total bilirubin >1.95 mg/dL, direct bilirubin >0.98
mg/dL, and ALT >200 U/mL were not statistically signiﬁcant,
nor was preconditioning total bilirubin >1.95 mg/dL. Total
bilirubin >1.95 mg/dL at 1 month (P < .0001), MAC condi-
tioning (P ¼ .005), primary graft failure (P < .0001), stem cell
source (P ¼ .02), SVI (P ¼ .039), BBSI (P < .0001), VOD (P ¼
.0047), and IFI (P ¼ .001) were all statistically signiﬁcant on
univariate analysis. Allo-HSCT performed between 2006 and
2011 had a trend toward lower TRM (P¼ .067). Age, sex, CMVTable 5
Multivariate Competing-Risk Regression on TRM after RIC/RTC versus MAC
in Pediatric Allo-HSCT Recipients
Variable OR 95% CI P Value
Primary graft failure
No 1
Yes 2.8 1.5-5.3 .001
SVI
No 1
Yes 2.2 1.0-4.5 .04
BBSI
No 1
Yes 2.4 1.3-4.2 .003
Total bilirubin (day 30)
1.95 mg/dL 1
>1.95 mg/dL 7.9 4.4-14.2 <.0001risk status, disease type, disease risk status, acute GVHD, and
chronic GVHD were not statistically signiﬁcant.
On multivariate competing-risk regression analysis, only
total bilirubin >1.95 mg/dL at 1 month (P < .0001), primary
graft failure (P ¼ .001), SVI (P ¼ .04), and BBSI (P ¼ .003)
remained signiﬁcant predictors of TRM (Table 5). Of note,
MAC conditioning was no longer a signiﬁcant risk factor for
TRM on multivariate analysis.
LI and TRM
Twenty-three of the 33 patients with a total bilirubin
>1.95 mg/dL at 1 month after allo-HSCT sustained TRM.
Further analysis of causes of death in these patients revealed
that the majority were related to infection. Speciﬁcally, 14 of
the 23 patients who died had a severe bacterial infection, 3
had a fungal infection, 2 had a viral infection, and 1 had
toxoplasmosis. In addition, 4 patients had VOD, and 1 patient
died secondary to intracranial hemorrhage from moyamoya
disease. Figure 1 shows the impact of LI at 1 month on TRM.
The 1-year probability of TRM was signiﬁcantly greater in
patients with LI at 1 month compared with those who did
not (60.7% [95% CI, 42.6% to 78.7%] versus 14.6% [95% CI, 9.9%
to 19.4%]; P < .0001).
DISCUSSION
The present study has examined the incidence and impact
of LI occurring before and after allo-HSCT in pediatric
recipients. To our knowledge, this is the largest study of
hepatic dysfunction and subsequent outcomes in pediatric
allo-HSCT recipients reported to date.
We used the National Cancer Institute’s Common Termi-
nology Criteria for Adverse Events 3.0/4.0 to deﬁne LI as
laboratory values indicative of grade 2 hyperbilirubinemia.
Similar to other studies [6], we found that total bilirubin, but
not ALT, was useful in predicting mortality after allo-HSCT.
Furthermore, preeallo-HSCT LI did not predict posteallo-
HSCT TRM.
Few previous studies have focused on preeallo-HSCT LI.
Barba et al. [6] reported that in adult allo-HSCT recipients,
pretransplantation elevations of bilirubin and g-glutamyl-
transpeptidase, but not of AST, ALT, or alkaline phosphatase,Figure 1. TRM stratiﬁed by presence of LI at 1 month.
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In the present study, we were unable to demonstrate the
impact of preeallo-HSCT LI on TRM in pediatric patients,
possibly because of our small study cohort or the fact that
patients with preeallo-HSCT LI might have been more likely
to receive RTC/RIC. Indeed, 14 of our 20 patients with
preeallo-HSCT LI received RTC/RIC. Conﬁrming this ﬁnding
in a larger prospective study will be important, considering
that pretransplantation ALT and bilirubin levels are eligibility
criteria for allo-HSCT, and transplantation is often delayed
until these laboratory values normalize.
In the present study, 33 patients (14.1%) had LI, deﬁned as
grade 2 hyperbilirubinemia, by 1 month after allo-HSCT.
The incidence of LI in our pediatric cohort was lower than
that reported previously in adult allo-HSCT recipients
[19,20]. In a study of 193 adult recipients of allo-HSCT with
nonmyeloablative conditioning, Hogan et al. [19] reported
severe hyperbilirubinemia (>4 mg/dL) in 24% and some
degree of hyperbilirubinemia (total bilirubin >1.2 mg/dL) in
84%. Similarly, Kusumi et al. [20] found that 87% of adult RIC
unrelated cord blood transplant recipients had a total serum
bilirubin level>1.2 mg/dL. In the present study, only 19.2% of
our pediatric patients had a total serum bilirubin level >1.2
mg/dL (data not shown). Furthermore, the incidence of post-
transplantation LI declined steeply over time, with rates of
2.9% at dayþ100 and only 2.3% at 1 year. This decrease in LI is
likely secondary to the high mortality rate associated with LI
at 1 month after allo-HSCT.
The 1-year TRM in our patients with LI at 1 month after
allo-HSCT was extremely high, at 60.7%. Furthermore, the
patients with TRM died early, by dayþ200 after allo-HSCT. In
an adult study, allo-HSCT recipients with extreme hyper-
bilirubinemia (>10 mg/dL) had a day þ200 TRM of 79%,
compared with 17% in those with total bilirubin <10 mg/dL
[8]. In the present study, the patients with LI at 1 month who
subsequently died had a median total bilirubin level of
5.33 mg/dL, and only 20% had extreme hyperbilirubinemia.
TRM was 100% in the patients with extreme hyper-
bilirubinemia. Taken together, our data suggest that pediatric
allo-HSCT recipients have a lower incidence of LI, but higher
associated TRM, compared with adult recipients.
BBSIs and ISIs were the most signiﬁcant risk factors for LI
in our pediatric allo-HSCT recipients. BBSI has been previ-
ously identiﬁed as a risk factor for LI [20], but the mechanism
for this remains unclear. It is plausible that during the early
posteallo-HSCT period, recipients of MAC have higher grades
of mucositis, which could lead to transmigration of gastro-
intestinal bacteria into the bloodstream, resulting in sepsis
[21]. The association between bacterial infection during the
ﬁrst 30 days after allo-HSCT and hyperbilirubinemia at
1 month and its impact on subsequent TRM is intriguing. It is
plausible that bacterial infections may start the cascade of
events that leads to hyperbilirubinemia and ultimately TRM.
Prospective studies of the associations among BBSI, LI, and
TRM are planned for the next few years.
Patients with IFI who subsequently develop LI likely fall
into 2 classes: those whose infection leads directly to LI and,
more frequently, those with antifungal-mediated LI. A recent
study of the hepatotoxicity of antifungal medications in bone
marrow transplant recipients found that both liposomal
amphotericin B and ﬂuconazole were associated with
a substantial increase in the risk of hepatotoxicity [22].
Further analysis demonstrated that in patients who devel-
oped hepatotoxicity and who continued receiving antifungal
therapy, marked hyperbilirubinemia developed in 33% of thepatients treated with liposomal amphotericin B, compared
with only 8% of those treated with ﬂuconazole.
Wewere interested in the role of conditioning regimen on
LI. Previous studies have implicated MAC regimens, TBI, and
methotrexate as risk factors for LI [23-26], and each of these
factors was signiﬁcantly associated with LI on univariate
analysis. Only TBI-containing conditioning regimens re-
mained signiﬁcant on multivariate analysis. However, MAC
and TBI-containing regimens were not associated with
a higher incidence of TRM when controlling for other risk
factors.
Previous studies have demonstrated the protective effect
of ursodiol and lowmolecular weight heparin in prophylactic
prevention of hepatic injury; however, these ﬁndings were
not duplicated in the present study. Ruutu et al. [27] reported
that fewer adult allo-HSCT recipients receiving ursodiol
developed hyperbilirubinemia (P ¼ .04) or grade III to IV
aGVHD (P¼ .01) compared with those not receiving ursodiol.
Similarly, Thornley et al. [28] found that pediatric allo-HSCT
recipients receiving prophylactic doses of ursodiol experi-
enced less severe hepatic toxicity (P ¼ .007). In the present
study, 37.3% of our pediatric allo-HSCT recipients received
prophylactic ursodiol, but univariate analysis showed no
protective effect (hazard ratio [HR], 1.137; P ¼ .7270). Simi-
larly, Simon et al. [29] reported that adult recipients of allo-
HSCT receiving prophylactic low molecular weight heparin
were at reduced risk of developing VOD (P ¼ .0005)
compared with those receiving heparin (P ¼ .002) or no
prophylaxis. In the present study, 41.3% of our patients
received enoxaparin, but univariate analysis showed no
protective effect (HR, 0.94; P ¼ .87), similar to previous
reports [15]. The lack of a protective effect of ursodiol on the
development of LI may be related to our small sample size,
however.
Limitations of this retrospective study include disparate
donor sources and disease risk status and lack of uniformity
in administration of ursodiol and enoxaparin. Because
subjects were heterogeneous in terms of underlying disease,
conditioning regimen, and hematopoietic stem cell donor
sources, this preliminary analysis should be replicated in
additional studies of children with more homogenous diag-
noses and cell sources. Another limitation of this study is that
we did not investigate causes of LI. LI may precede allo-HSCT,
with causes including chronic hepatitis B and C infection,
fungal infection, previous chemotherapy, and previous
radiation therapy, or may occur after allo-HSCT from the
conditioning chemotherapy regimen, VOD, GVHD, adminis-
tration of total parenteral nutrition, ischemia, drug-induced
hepatic injury, or infection [30-32]. We are planning
a prospective study of causes of LI in children at our center in
an attempt to better identify prophylactic and therapeutic
measures to decrease the incidence and improve outcomes
for these patients.
In summary, in our study cohort, early LI was strongly
associated with early TRM, and BBSI and IFI were the primary
risk factors for LI. These ﬁndings underscore the crucial need
to further minimize bloodstream infections. Various strate-
gies are currently used to decrease bloodstream infections
[33]. The National Association of Children’s Hospitals and
Related Institutions is working to minimize bloodstream
infections secondary to catheters and central lines by stan-
dardizing procedures for dressing changes and obtaining
blood from central lines. In addition, an ongoing study by the
Children’s Oncology Group is evaluating the toxicity and
efﬁcacy of levoﬂoxacin in decreasing bacteremia in pediatric
K. Radhakrishnan et al. / Biol Blood Marrow Transplant 19 (2013) 912e917 917allo-HSCT recipients. At our institution, as we determine
which organisms are able to cause breakthrough infections
in patients already receiving ongoing prophylactic antifungal
and antibacterial agents, we will seek to develop alternative
prophylactic and/or therapeutic regimens. Together, these
approaches should serve to further decrease the incidence of
LI, and thus TRM, in pediatric allo-HSCT recipients.
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